Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO Subscriptions PDA Services My JCO Customer Service

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Le Chevalier, T.
Right arrow Articles by Cigolari, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Le Chevalier, T.
Right arrow Articles by Cigolari, S.

Journal of Clinical Oncology, Vol 12, 360-367, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Randomized study of vinorelbine and cisplatin versus vindesine and cisplatin versus vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicenter trial including 612 patients

T Le Chevalier, D Brisgand, JY Douillard, JL Pujol, V Alberola, A Monnier, A Riviere, P Lianes, P Chomy and S Cigolari
Department of Medicine, Institut Gustave-Roussy, Villejuif, France.

PURPOSE: We designed a prospective randomized trial to compare vinorelbine and cisplatin (NVB-P) with vindesine and cisplatin (VDS-P) and to evaluate whether the best of these regimens affords a survival benefit compared with vinorelbine alone (NVB), an outpatient regimen, in patients with non-small-cell lung cancer (NSCLC). PATIENTS AND METHODS: Forty-five centers included 612 patients in this study: 206 on NVB-P, 200 on VDS-P, and 206 on NVB. Vinorelbine was administered at a dose of 30 mg/m2 weekly, cisplatin at 120 mg/m2 on days 1 and 29 and then every 6 weeks, and vindesine at 3 mg/m2 weekly for 6 weeks and then every other week. Treatment was continued until progression or toxicity. Four percent of the patients entered were ineligible and 59% had metastatic disease. RESULTS: An objective response rate was observed in 30% of patients in the NVB-P arm versus 19% in the VDS-P arm (P = .02) and 14% in the NVB arm (P < .001). The median duration of survival was 40 weeks in the NVB-P arm, compared with 32 weeks in the VDS-P arm and 31 weeks in the NVB arm. Comparison of survival among the three groups demonstrated an advantage for NVB-P compared with VDS-P (P = .04) and NVB (P = .01). Neutropenia was significantly higher in the NVB-P group (P < .001), and neurotoxicity was more frequent with VDS-P (P < .004). CONCLUSION: Since our results have demonstrated that NVB-P yields a longer survival duration and a higher response rate than VDS-P or NVB alone, with acceptable toxicity, this combination should be considered a relevant regimen in advanced NSCLC.


This article has been cited by other articles:


Home page
 JCOHome page
R. Ramlau, P. Zatloukal, J. Jassem, P. Schwarzenberger, S. V. Orlov, M. Gottfried, J. R. Pereira, G. Temperley, R. Negro-Vilar, S. Rahal, et al.
Randomized Phase III Trial Comparing Bexarotene (L1069-49)/Cisplatin/Vinorelbine With Cisplatin/Vinorelbine in Chemotherapy-Naive Patients With Advanced or Metastatic Non-Small-Cell Lung Cancer: SPIRIT I
J. Clin. Oncol., April 10, 2008; 26(11): 1886 - 1892.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Hirai, K. Komura, A. Tokoro, T. Kuromaru, A. Ohshima, T. Ito, Y. Sumiyoshi, and I. Hyodo
Psychological and behavioral mechanisms influencing the use of complementary and alternative medicine (CAM) in cancer patients
Ann. Onc., January 1, 2008; 19(1): 49 - 55.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Fujiwara, I. Sekine, K. Tsuta, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, K. Yamada, and T. Tamura
Effect of Platinum Combined with Irinotecan or Paclitaxel against Large Cell Neuroendocrine Carcinoma of the Lung
Jpn. J. Clin. Oncol., July 24, 2007; (2007) hym053v1.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
Y. Fujiwara, I. Sekine, Y. Ohe, H. Kunitoh, N. Yamamoto, H. Nokihara, Y. Simmyo, T. Fukui, K. Yamada, and T. Tamura
Serum Total Bilirubin as a Predictive Factor for Severe Neutropenia in Lung Cancer Patients Treated with Cisplatin and Irinotecan
Jpn. J. Clin. Oncol., May 30, 2007; (2007) hym033v1.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
S. Kudoh
In Reply
J. Clin. Oncol., April 10, 2007; 25(11): 1446 - 1446.
[Full Text] [PDF]

Home page
 The OncologistHome page
F. Grossi, M. Aita, A. Follador, C. Defferrari, A. Brianti, G. Sinaccio, and O. Belvedere
Sequential, Alternating, and Maintenance/Consolidation Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Review of the Literature
Oncologist, April 1, 2007; 12(4): 451 - 464.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Langer, S. Li, J. Schiller, W. Tester, B. L. Rapoport, and D. H. Johnson
Randomized Phase II Trial of Paclitaxel Plus Carboplatin or Gemcitabine Plus Cisplatin in Eastern Cooperative Oncology Group Performance Status 2 Non-Small-Cell Lung Cancer Patients: ECOG 1599
J. Clin. Oncol., February 1, 2007; 25(4): 418 - 423.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P Comella, G Filippelli, G De Cataldis, B Massidda, G Frasci, L Maiorino, C Putzu, S Mancarella, S Palmeri, R Cioffi, et al.
Efficacy of the combination of cisplatin with either gemcitabine and vinorelbine or gemcitabine and paclitaxel in the treatment of locally advanced or metastatic non-small-cell lung cancer: a phase III randomised trial of the Southern Italy Cooperative Oncology Group (SICOG 0101)
Ann. Onc., February 1, 2007; 18(2): 324 - 330.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y Ohe, Y Ohashi, K Kubota, T Tamura, K Nakagawa, S Negoro, Y Nishiwaki, N Saijo, Y Ariyoshi, M Fukuoka, et al.
Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan
Ann. Onc., February 1, 2007; 18(2): 317 - 323.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
P. N. Chhajed, F. Baty, M. Pless, S. Somandin, M. Tamm, and M. H. Brutsche
Outcome of Treated Advanced Non-small Cell Lung Cancer With and Without Central Airway Obstruction
Chest, December 1, 2006; 130(6): 1803 - 1807.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. R. Green, G. M. Manikhas, S. Orlov, B. Afanasyev, A. M. Makhson, P. Bhar, and M. J. Hawkins
Abraxane(R), a novel Cremophor(R)-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer
Ann. Onc., August 1, 2006; 17(8): 1263 - 1268.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. L. Visbal, N. B. Leighl, R. Feld, and F. A. Shepherd
Adjuvant Chemotherapy for Early-Stage Non-small Cell Lung Cancer
Chest, October 1, 2005; 128(4): 2933 - 2943.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Fournel, G. Robinet, P. Thomas, P.-J. Souquet, H. Lena, A. Vergnenegre, J.-Y. Delhoume, J. Le Treut, J.-A. Silvani, E. Dansin, et al.
Randomized Phase III Trial of Sequential Chemoradiotherapy Compared With Concurrent Chemoradiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study
J. Clin. Oncol., September 1, 2005; 23(25): 5910 - 5917.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
C. Gridelli and F. A. Shepherd
Chemotherapy for Elderly Patients With Non-Small Cell Lung Cancer: A Review of the Evidence
Chest, August 1, 2005; 128(2): 947 - 957.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
B. Besse, J. C. Soria, and T. Le Chevalier
Front-line doublets in advanced non-small cell lung cancer: The golden age for second line chemotherapy
Ann. Onc., July 1, 2005; 16(7): 997 - 998.
[Full Text] [PDF]

Home page
 NEJMHome page
T. Winton, R. Livingston, D. Johnson, J. Rigas, M. Johnston, C. Butts, Y. Cormier, G. Goss, R. Inculet, E. Vallieres, et al.
Vinorelbine plus Cisplatin vs. Observation in Resected Non-Small-Cell Lung Cancer
N. Engl. J. Med., June 23, 2005; 352(25): 2589 - 2597.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Gridelli, M. Aapro, A. Ardizzoni, L. Balducci, F. De Marinis, K. Kelly, T. Le Chevalier, C. Manegold, F. Perrone, R. Rosell, et al.
Treatment of Advanced Non-Small-Cell Lung Cancer in the Elderly: Results of an International Expert Panel
J. Clin. Oncol., May 1, 2005; 23(13): 3125 - 3137.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Platinums in Lung Cancer: Sufficient or Necessary?
J. Clin. Oncol., May 1, 2005; 23(13): 2882 - 2883.
[Full Text] [PDF]

Home page
 JCOHome page
V. Georgoulias, A. Ardavanis, X. Tsiafaki, A. Agelidou, P. Mixalopoulou, O. Anagnostopoulou, P. Ziotopoulos, M. Toubis, K. Syrigos, N. Samaras, et al.
Vinorelbine Plus Cisplatin Versus Docetaxel Plus Gemcitabine in Advanced Non-Small-Cell Lung Cancer: A Phase III Randomized Trial
J. Clin. Oncol., May 1, 2005; 23(13): 2937 - 2945.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G. D'Addario, M. Pintilie, N. B. Leighl, R. Feld, T. Cerny, and F. A. Shepherd
Platinum-Based Versus Non-Platinum-Based Chemotherapy in Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of the Published Literature
J. Clin. Oncol., May 1, 2005; 23(13): 2926 - 2936.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
J. R. Goffin, I. C. Anderson, J. G. Supko, J. P. Eder Jr., G. I. Shapiro, T. J. Lynch, M. Shipp, B. E. Johnson, and A. T. Skarin
Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., May 1, 2005; 11(9): 3417 - 3424.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
D. H. Lee, J.-Y. Han, H. G. Lee, J. J. Lee, E. K. Lee, H. Y. Kim, H. K. Kim, E. K. Hong, and J. S. Lee
Gefitinib as a First-Line Therapy of Advanced or Metastatic Adenocarcinoma of the Lung in Never-Smokers
Clin. Cancer Res., April 15, 2005; 11(8): 3032 - 3037.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
V. Westeel, E. Quoix, D. Moro-Sibilot, M. Mercier, J.-L. Breton, D. Debieuvre, P. Richard, M.-A. Haller, B. Milleron, D. Herman, et al.
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
J Natl Cancer Inst, April 6, 2005; 97(7): 499 - 506.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-L. Pujol, J.-L. Breton, R. Gervais, P. Rebattu, A. Depierre, J.-F. Morere, B. Milleron, D. Debieuvre, D. Castera, P.-J. Souquet, et al.
Gemcitabine-docetaxel versus cisplatin-vinorelbine in advanced or metastatic non-small-cell lung cancer: a phase III study addressing the case for cisplatin
Ann. Onc., April 1, 2005; 16(4): 602 - 610.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
F. Waechter, J. Passweg, M. Tamm, M. Brutsche, R. Herrmann, and M. Pless
Significant Progress in Palliative Treatment of Non-small Cell Lung Cancer in the Past Decade
Chest, March 1, 2005; 127(3): 738 - 747.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J.-Y. Douillard, R. Gervais, G. Dabouis, A. Le Groumellec, M. D'Arlhac, D. Spaeth, B. Coudert, D. Caillaud, A. Monnier, C. Clary, et al.
Sequential two-line strategy for stage IV non-small-cell lung cancer: docetaxel-cisplatin versus vinorelbine-cisplatin followed by cross-over to single-agent docetaxel or vinorelbine at progression: final results of a randomised phase II study
Ann. Onc., January 1, 2005; 16(1): 81 - 89.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
K. Hotta, K. Matsuo, H. Ueoka, K. Kiura, M. Tabata, and M. Tanimoto
Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials
Ann. Onc., December 1, 2004; 15(12): 1782 - 1789.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
L. B. Marks, J. Garst, M. A. Socinski, G. Sibley, A. W. Blackstock, J. E. H. S. Zhou, T. Shafman, A. Tisch, R. Clough, X. Yu, et al.
Carboplatin/Paclitaxel or Carboplatin/Vinorelbine Followed by Accelerated Hyperfractionated Conformal Radiation Therapy: Report of a Prospective Phase I Dose Escalation Trial From the Carolina Conformal Therapy Consortium
J. Clin. Oncol., November 1, 2004; 22(21): 4329 - 4340.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
M. A. Villalona-Calero, P. Ritch, J. A. Figueroa, G. A. Otterson, R. Belt, E. Dow, S. George, J. Leonardo, S. McCachren, G. L. Miller, et al.
A Phase I/II Study of LY900003, an Antisense Inhibitor of Protein Kinase C-{alpha}, in Combination with Cisplatin and Gemcitabine in Patients with Advanced Non-Small Cell Lung Cancer
Clin. Cancer Res., September 15, 2004; 10(18): 6086 - 6093.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. Morris, J. A. Blessing, B. J. Monk, R. McGehee, and D. H. Moore
Phase II Study of Cisplatin and Vinorelbine in Squamous Cell Carcinoma of the Cervix: A Gynecologic Oncology Group Study
J. Clin. Oncol., August 15, 2004; 22(16): 3340 - 3344.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
C. Delbaldo, S. Michiels, N. Syz, J.-C. Soria, T. Le Chevalier, and J.-P. Pignon
Benefits of Adding a Drug to a Single-Agent or a 2-Agent Chemotherapy Regimen in Advanced Non-Small-Cell Lung Cancer: A Meta-analysis
JAMA, July 28, 2004; 292(4): 470 - 484.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Georgoulias, A. Ardavanis, A. Agelidou, M. Agelidou, V. Chandrinos, E. Tsaroucha, M. Toumbis, C. Kouroussis, K. Syrigos, A. Polyzos, et al.
Docetaxel Versus Docetaxel Plus Cisplatin As Front-Line Treatment of Patients With Advanced Non--Small-Cell Lung Cancer: A Randomized, Multicenter Phase III Trial
J. Clin. Oncol., July 1, 2004; 22(13): 2602 - 2609.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
G. P. Stathopoulos, M. Veslemes, N. Georgatou, D. Antoniou, P. Giamboudakis, K. Katis, D. Tsavdaridis, S. K. Rigatos, I. Dimitroulis, S. Bastani, et al.
Front-line paclitaxel-vinorelbine versus paclitaxel-carboplatin in patients with advanced non-small-cell lung cancer: a randomized phase III trial
Ann. Onc., July 1, 2004; 15(7): 1048 - 1055.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Laack, N. Dickgreber, T. Muller, A. Knuth, J. Benk, C. Lorenz, F. Gieseler, H. Durk, W. Engel-Riedel, K. Dalhoff, et al.
Randomized Phase III Study of Gemcitabine and Vinorelbine Versus Gemcitabine, Vinorelbine, and Cisplatin in the Treatment of Advanced Non-Small-Cell Lung Cancer: From the German and Swiss Lung Cancer Study Group
J. Clin. Oncol., June 15, 2004; 22(12): 2348 - 2356.
[Abstract] [Full Text] [PDF]

Home page
 Jpn J Clin OncolHome page
K. Yoh, S. Niho, K. Goto, H. Ohmatsu, K. Kubota, R. Kakinuma, and Y. Nishiwaki
High Body Mass Index Correlates with Increased Risk of Venous Irritation by Vinorelbine Infusion
Jpn. J. Clin. Oncol., April 1, 2004; 34(4): 206 - 209.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. Harper, T. Plunkett, and D. Khayat
In Reply:
J. Clin. Oncol., April 1, 2004; 22(7): 1347 - 1347.
[Full Text] [PDF]

Home page
 Ann OncolHome page
C. Gridelli, A. Ardizzoni, T. Le Chevalier, C. Manegold, F. Perrone, N. Thatcher, N. van Zandwijk, M. Di Maio, O. Martelli, and F. De Marinis
Treatment of advanced non-small-cell lung cancer patients with ECOG performance status 2: results of an European Experts Panel
Ann. Onc., March 1, 2004; 15(3): 419 - 426.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
D. G. Pfister, D. H. Johnson, C. G. Azzoli, W. Sause, T. J. Smith, S. Baker Jr, J. Olak, D. Stover, J. R. Strawn, A. T. Turrisi, et al.
American Society of Clinical Oncology Treatment of Unresectable Non-Small-Cell Lung Cancer Guideline: Update 2003
J. Clin. Oncol., January 15, 2004; 22(2): 330 - 353.
[Full Text] [PDF]

Home page
 JCOHome page
K. Kubota, K. Watanabe, H. Kunitoh, K. Noda, Y. Ichinose, N. Katakami, T. Sugiura, M. Kawahara, A. Yokoyama, S. Yokota, et al.
Phase III Randomized Trial of Docetaxel Plus Cisplatin Versus Vindesine Plus Cisplatin in Patients With Stage IV Non-Small-Cell Lung Cancer: The Japanese Taxotere Lung Cancer Study Group
J. Clin. Oncol., January 15, 2004; 22(2): 254 - 261.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
Y. Ohe, S. Niho, R. Kakinuma, K. Kubota, H. Ohmatsu, K. Goto, H. Nokihara, H. Kunitoh, N. Saijo, H. Aono, et al.
A phase II study of cisplatin and docetaxel administered as three consecutive weekly infusions for advanced non-small-cell lung cancer in elderly patients
Ann. Onc., January 1, 2004; 15(1): 45 - 50.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
J. Jassem, P. Kosmidis, R. Ramlau, K. Zarogoulidis, L. Novakova, J. Breton, P.-L. Etienne, C. Seebacher, M. Grivaux, A. Ojala, et al.
Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer
Ann. Onc., November 1, 2003; 14(11): 1634 - 1639.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
V. Alberola, C. Camps, M. Provencio, D. Isla, R. Rosell, C. Vadell, I. Bover, A. Ruiz-Casado, P. Azagra, U. Jimenez, et al.
Cisplatin Plus Gemcitabine Versus a Cisplatin-Based Triplet Versus Nonplatinum Sequential Doublets in Advanced Non-Small-Cell Lung Cancer: A Spanish Lung Cancer Group Phase III Randomized Trial
J. Clin. Oncol., September 1, 2003; 21(17): 3207 - 3213.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. Gridelli, C. Gallo, F. A. Shepherd, A. Illiano, F. Piantedosi, S. F. Robbiati, L. Manzione, S. Barbera, L. Frontini, E. Veltri, et al.
Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group
J. Clin. Oncol., August 15, 2003; 21(16): 3025 - 3034.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
F. Fossella, J. R. Pereira, J. von Pawel, A. Pluzanska, V. Gorbounova, E. Kaukel, K. V. Mattson, R. Ramlau, A. Szczesna, P. Fidias, et al.
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non-Small-Cell Lung Cancer: The TAX 326 Study Group
J. Clin. Oncol., August 15, 2003; 21(16): 3016 - 3024.
[Abstract] [Full Text] [PDF]

Home page
 The OncologistHome page
B.T. Hennessy, E.O. Hanrahan, and O.S. Breathnach
Chemotherapy Options for the Elderly Patient with Advanced Non-Small Cell Lung Cancer
Oncologist, June 1, 2003; 8(3): 270 - 277.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
C. Gridelli, F. Perrone, C. Gallo, S. Cigolari, A. Rossi, F. Piantedosi, S. Barbera, F. Ferrau, E. Piazza, F. Rosetti, et al.
Chemotherapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Multicenter Italian Lung Cancer in the Elderly Study (MILES) Phase III Randomized Trial
J Natl Cancer Inst, March 5, 2003; 95(5): 362 - 372.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
M. J. Millward, M. J. Boyer, M. Lehnert, S. Clarke, D. Rischin, B.-C. Goh, J. Wong, E. McNeil, and J. F. Bishop
Docetaxel and carboplatin is an active regimen in advanced non-small-cell lung cancer: a phase II study in Caucasian and Asian patients
Ann. Onc., March 1, 2003; 14(3): 449 - 454.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
E. F. Smit, K. Mattson, J. von Pawel, C. Manegold, S. Clarke, and P. E. Postmus
ALIMTA(R) (pemetrexed disodium) as second-line treatment of non-small-cell lung cancer: a phase II study
Ann. Onc., March 1, 2003; 14(3): 455 - 460.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. A. Socinski, D. E. Morris, G. A. Masters, and R. Lilenbaum
Chemotherapeutic Management of Stage IV Non-small Cell Lung Cancer
Chest, January 1, 2003; 123(1_suppl): 226S - 243S.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. J. Souquet, E. H. Tan, J. Rodrigues Pereira, R. Van Klaveren, A. Price, U. Gatzemeier, M. Jaworski, J. P. Burillon, and D. Aubert
GLOB-1: a prospective randomised clinical phase III trial comparing vinorelbine-cisplatin with vinorelbine-ifosfamide-cisplatin in metastatic non-small-cell lung cancer patients
Ann. Onc., December 1, 2002; 13(12): 1853 - 1861.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
G.V. Scagliotti, F. De Marinis, M. Rinaldi, L. Crino, C. Gridelli, S. Ricci, E. Matano, C. Boni, M. Marangolo, G. Failla, et al.
Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non-Small-Cell Lung Cancer
J. Clin. Oncol., November 1, 2002; 20(21): 4285 - 4291.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. E. Vokes, J. E. Herndon II, J. Crawford, K. A. Leopold, M. C. Perry, A. A. Miller, and M. R. Green
Randomized Phase II Study of Cisplatin With Gemcitabine or Paclitaxel or Vinorelbine as Induction Chemotherapy Followed by Concomitant Chemoradiotherapy for Stage IIIB Non-Small-Cell Lung Cancer: Cancer and Leukemia Group B Study 9431
J. Clin. Oncol., October 15, 2002; 20(20): 4191 - 4198.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
P. A. Bunn Jr
Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Who, What, When, Why?
J. Clin. Oncol., September 15, 2002; 20(90001): 23s - 33.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
J. D. Hainsworth, J. R. Gray, L. H. Morrissey, L. A. Kalman, J. K. Hon, and F. A. Greco
Long-Term Follow-Up of Patients Treated With Paclitaxel/Carboplatin-Based Chemotherapy for Advanced Non-Small-Cell Lung Cancer: Sequential Phase II Trials of the Minnie Pearl Cancer Research Network
J. Clin. Oncol., July 1, 2002; 20(13): 2937 - 2942.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
M. A. Socinski, M. J. Schell, A. Peterman, K. Bakri, S. Yates, R. Gitten, P. Unger, J. Lee, J.-H. Lee, M. Tynan, et al.
Phase III Trial Comparing a Defined Duration of Therapy Versus Continuous Therapy Followed by Second-Line Therapy in Advanced-Stage IIIB/IV Non-Small-Cell Lung Cancer
J. Clin. Oncol., March 1, 2002; 20(5): 1335 - 1343.
[Abstract] [Full Text] [PDF]